Antibiotic dosage in trachoma control programs:: Height as a surrogate for weight in children

被引:22
作者
Muñoz, B
Solomon, AW
Zingeser, J
Barwick, R
Burton, M
Bailey, R
Mabey, D
Foster, A
West, SK
机构
[1] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA
[2] London Sch Hyg & Trop Med, London WC1, England
[3] Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania
[4] Huruma Hosp, Rombo, Tanzania
[5] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA
[6] MRC Labs, Banjul, Gambia
基金
英国惠康基金;
关键词
D O I
10.1167/iovs.02-0234
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. National programs for trachoma control are implementing mass treatment programs in which azithromycin is used as part of the control strategy. Dose is determined by weight, which can be difficult to determine in field conditions. The purposes of this study were to determine whether an accurate dose could be determined by using height as. a Surrogate for weight and whether a single model of height-based dosage would be applicable in more than one setting. METHODS. Data on height, weight, age, and gender of 5558 children aged 6 months to 15 years were obtained from Kongwa and Rombo, Tanzania; Malakal, Sudan; Jareng, The Gambia; and Daboya, Ghana. Models for predicting weight by measuring height were developed that incorporated country-specific parameters. Doses of azithromycin assumed suspension of 40 mg/mL and 250-mg tablets that could be halved. Tolerance limits were defined as 15 to 30 mg/kg. RESULTS. A regression model, predicting log weight as a function of log height, was the best fit and explained 94% of the variance. In children less than 1 year of age or 60 cm in height, dose determined by weight was preferred. Dosage by height resulted in more than 97% of children receiving doses within the tolerance limits. Children aged 1 to 2 years were the group most likely to be over- or undermedicated, but this occurred in only 6% of this age group. CONCLUSIONS. Height-based determination of dosage of azithromycin in trachoma control programs appears to be feasible, using the height-based schedule proposed. One model was adequate for all the countries in the study. Further expansion to other countries is warranted.
引用
收藏
页码:1464 / 1469
页数:6
相关论文
共 9 条
  • [1] ALEXANDER NDE, 1993, B WORLD HEALTH ORGAN, V71, P361
  • [2] COUSENS SN, 1994, INT OPHTHALMOL, V18, P215
  • [3] Alternatives to bodyweight for estimating the dose of praziquantel needed to treat schistosomiasis
    Hall, A
    Nokes, C
    Wenz, ST
    Adjei, S
    Kihamia, C
    Mwanri, L
    Bobrow, E
    de Graft-Johnson, J
    Bundy, D
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (06) : 653 - 658
  • [4] Azithromycin in control of trachoma
    Schachter, J
    West, SK
    Mabey, D
    Dawson, CR
    Bobo, L
    Bailey, R
    Vitale, S
    Quinn, TC
    Sheta, A
    Sallam, S
    Mkocha, H
    Mabey, D
    Faal, H
    [J]. LANCET, 1999, 354 (9179) : 630 - 635
  • [5] Community based ivermectin therapy for onchocerciasis: Comparison of three methods of dose assessment
    Shu, EN
    Okonkwo, PO
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 65 (03) : 184 - 188
  • [6] Solomon AW, 2001, B WORLD HEALTH ORGAN, V79, P8
  • [7] SIMPLIFIED DOSE SCHEDULE OF IVERMECTIN
    TAYLOR, HR
    GONZALES, C
    DUKE, B
    [J]. LANCET, 1993, 341 (8836) : 50 - 51
  • [8] THE EPIDEMIOLOGY OF TRACHOMA IN CENTRAL TANZANIA
    WEST, SK
    MUNOZ, B
    TURNER, VM
    MMBAGA, BBO
    TAYLOR, HR
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1991, 20 (04) : 1088 - 1092
  • [9] World Health Organization, 1998, WHO 51 WORLD HLTH AS